Submission deadline
The regular abstract submission deadline is on 2nd of March 2026.
List of accepted Abstract Topics:
- Real-world experience, novel clinical approaches and combination therapies - Potential synergy b/n engineered lymphocytes & other treatment modalities will be demonstrated.
- Superpowered lymphocytes - Learn more about engineering of lymphocytes for the co-expression of varied immune effectors in addition to the transgenic receptor.
- Non-viral CAR/TCR gene targeting - Recent advancement in promoting integrations into lymphocyte genomes by means of nucleases or transposons.
- CAR/TCR mRNA therapies - Exploring the therapeutic effects of transient CAR/TCR expression using mRNA delivery.
- In Vivo Lymphocyte Engineering - Explores emerging technologies that enable precise genetic modification of lymphocytes directly within the body to simplify and broaden therapeutic application.
- Targeting Autoimmune Diseases - Examines how engineered lymphocytes can be designed to restore immune balance and counteract the pathological responses underlying autoimmune conditions.
- HSC Genetic Engineering and Epitope Editing - Highlights advances in editing hematopoietic stem cells to create durable immune lineages with tailored antigens or tailored receptors.
- Beyond alpha-beta T cells - Discuss the engineering of alternative leukocytes including Gamma-Delta T cells, iNKT cells, NK cells, B cells and macrophages.
- Advanced TCR Engineering - Targeting of non-malignant diseases, including infectious diseases, auto-immune diseases, cardiovascular diseases, genetic disorders and more.
Don't miss your chance to get your work published!
All accepted abstracts from ICLE 2026 will be published in Human Gene Therapy.
